Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. The stock has 8 warning signs investors should review. Among 277 Healthcare Providers & Services companies, Resonance Health ranks worse than 361010.47% on this metric.
Resonance Health's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Resonance Health's 5-Year Yield-on-Cost % or its related term are showing as below:
ASX:RHT's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.93 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Resonance Health (ASX:RHT) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Resonance Health 5-Year Yield-on-Cost % Related Terms
ASX:RHT vs VEEV, BTSG, HQY: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, Resonance Health's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Resonance Health's 5-Year Yield-on-Cost % falls into.
Resonance Health 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Resonance Health (ASX:RHT) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #999999 out of 277 companies in the Healthcare Providers & Services industry.
Is Resonance Health's 5-Year Yield-on-Cost % too high?
Resonance Health's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Resonance Health ranks #999999 out of 277 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Resonance Health's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #999999 out of 277 companies for 5-Year Yield-on-Cost %. This places Resonance Health in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
